KALA BIO, Inc. — Director's Dealing 2017

Jul 19, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19

Reporting Person: LaRussa Michele (Sr. VP, Regulatory and Quality)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$3.34	2026-11-02	Common Stock (126115)		Direct

Footnotes

F1: This option was granted on November 2, 2016 and vests over four years, with 25% of the shares underlying the option vesting on October 11, 2017, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.